menu
    • menu
    [{"orgOrder":0,"company":"ProteoNic","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant protein","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ Immunomedics","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ Immunomedics"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"GIGA-2050","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ ProteoNic","highestDevelopmentStatusID":"6","companyTruncated":"ProteoNic \/ ProteoNic"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant Polyclonal Antibody","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ GigaGen"}]

    Find Clinical Drug Pipeline Developments & Deals by ProteoNic

    Menu

    ProteoNic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    ProteoNic

    Netherlands arrow
    Bio-Europe Spring
    Not Confirmed

    ProteoNic

    Netherlands arrow
    Bio-Europe Spring
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Recombinant Polyclonal Antibody

    Therapeutic Area : Technology

    Study Phase : Undisclosed

    Sponsor : GigaGen

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic™ Technology

    Details : Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.

    Product Name : Undisclosed

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    November 01, 2022

    Lead Product(s) : Recombinant Polyclonal Antibody

    Therapeutic Area : Technology

    Highest Development Status : Undisclosed

    Sponsor : GigaGen

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    ProteoNic

    Netherlands arrow
    Bio-Europe Spring
    Not Confirmed

    ProteoNic

    Netherlands arrow
    Bio-Europe Spring
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GIGA-2050

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Recipient : GigaGen

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- an...

    Details : Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic’s technology platform for the development and manufacturing of GigaGen’s recombinant antibody drugs including GIGA-2050.

    Product Name : GIGA-2050

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    September 30, 2021

    Lead Product(s) : GIGA-2050

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Recipient : GigaGen

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    ProteoNic

    Netherlands arrow
    Bio-Europe Spring
    Not Confirmed

    ProteoNic

    Netherlands arrow
    Bio-Europe Spring
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Recombinant protein

    Therapeutic Area : Oncology

    Study Phase : Undisclosed

    Sponsor : Immunomedics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics

    Details : Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.

    Product Name : Undisclosed

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    October 20, 2020

    Lead Product(s) : Recombinant protein

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Sponsor : Immunomedics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth